Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Kestra Medical Technologies (KMTS) Interest & Investment Income (2024 - 2026)

Kestra Medical Technologies (KMTS) has disclosed Interest & Investment Income for 3 consecutive years, with $2.2 million as the latest value for Q1 2026.

  • Quarterly Interest & Investment Income rose 244.43% to $2.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $7.8 million through Jan 2026, changed N/A year-over-year, with the annual reading at $3.2 million for FY2025, N/A changed from the prior year.
  • Interest & Investment Income for Q1 2026 was $2.2 million at Kestra Medical Technologies, up from $1.8 million in the prior quarter.
  • The five-year high for Interest & Investment Income was $2.2 million in Q3 2025, with the low at $37000.0 in Q3 2024.
  • Average Interest & Investment Income over 3 years is $1.3 million, with a median of $1.7 million recorded in 2025.
  • Peak annual rise in Interest & Investment Income hit 5756.76% in 2025, while the deepest fall reached 104.56% in 2025.
  • Over 3 years, Interest & Investment Income stood at $878000.0 in 2024, then skyrocketed by 104.56% to $1.8 million in 2025, then increased by 20.43% to $2.2 million in 2026.
  • According to Business Quant data, Interest & Investment Income over the past three periods came in at $2.2 million, $1.8 million, and $2.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.